Small molecule · developed by Janssen Res And Dev
Cyclobenzaprine is a centrally acting skeletal muscle relaxant that acts primarily at the brain stem to reduce tonic somatic motor activity, influencing both gamma and alpha motor systems. It is studied in primary fibromyalgia, post-traumatic stress disorder, and healthy adults, including sublingual and intravenous formulations.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Sep 1, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03841773 | Phase 3 | PTSD | Terminated | TNXP |
| NCT02589275 | Phase 3 | Primary Fibromyalgia | Completed | TNXP |
| NCT03443960 | Phase 1 | Healthy Subjects | Completed | TNXP |
| NCT01889173 | Phase 1 | Healthy Adults | Completed | TNXP |
| NCT01689259 | Phase 1 | Healthy Adults | Completed | TNXP |
| NCT01634412 | Phase 1 | Healthy Adults | Completed | TNXP |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy AdultsHealthy SubjectsPrimary FibromyalgiaPTSD
Updated Nov 15, 2026.